Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
Returns on capital
Opus Genetics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-323.1%
avg -164.4%
ROIC
-90.9%
avg -47.4%
ROA
-98.7%
avg -134.2%
Analysis
ROIC is currently the strongest return metric at -90.9% versus its period average of -47.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
George Magrath | Chief Executive Officer & Director | USD 973.79K | 41 | 2.01M | 2.44% |
Ashwath Jayagopal | Chief Scientific & Development Officer | USD 682.36K | 43 | 509.23K | 0.62% |
Joseph K. Schachle | Chief Operating Officer | USD 635.92K | 61 | 286.67K | 0.35% |
Amy Zaremba Rabourn | Head of Financial Quality Assurance | USD 434.1K | 45 | 188.67K | 0.23% |
Bernhard Hoffmann | Senior Vice President of Corporate Development & Secretary | USD 434.1K | 70 | 29.50K | 0.04% |
Andrew Murphy | Chief Scientific Officer | — | — | — | — |
Benjamin R. Yerxa | President & Director | — | 60 | 670.92K | 0.81% |
Chris Ernst | Chief Technology Officer | — | — | — | — |
Robert E. Gagnon | Chief Financial Officer & Principal Accounting Officer | — | 52 | 542.38K | 0.66% |
Bindu Manne | Head of Market Development & Commercialization | — | — | — | — |
Jenny Kobin | Investor Relations Officer | — | — | — | — |
Sally Tucker | Chief Medical Officer & Senior Vice President of Clinical Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$323,693.40
Sells
24
$19.68M
Net Transaction Value
−$19.35M
Net selling
Most Active
Magrath George
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 3, 26Nov 3, 2026 | Magrath George Direct | Sell | $110.2K$110,183.59 |
| Oct 23, 26Oct 23, 2026 | SCHACHLE JOSEPH K Direct | Sell | $17K$16,994.36 |
| Oct 23, 26Oct 23, 2026 | YERXA BENJAMIN R Direct | Sell | $27.2K$27,235.69 |
| Oct 23, 26Oct 23, 2026 | YERXA BENJAMIN R Direct | Sell | $90.1K$90,128.98 |
| Oct 23, 26Oct 23, 2026 | Gagnon Robert E. Direct | Sell | $49.6K$49,649.60 |
| Oct 23, 26Oct 23, 2026 | Magrath George Direct | Sell | $34.4K$34,383.74 |
| Sep 30, 26Sep 30, 2026 | Foundation Fighting Blindness Retinal Degeneration Fund Direct | Sell | $2.8M$2,755,980.80 |
| Sep 3, 26Sep 3, 2026 | Gagnon Robert E. Direct | Sell | $127.2K$127,212.40 |
| Jul 23, 26Jul 23, 2026 | YERXA BENJAMIN R Direct | Sell | $22.1K$22,064.13 |
| Jul 23, 26Jul 23, 2026 | SCHACHLE JOSEPH K Direct | Sell | $13.7K$13,653.36 |
1–10 of 26
Summary
Insiders reported 2 buys worth $323,693.40 and 24 sells worth $19.68M over the last 12 months. That adds up to net selling of $19.35M. Magrath George was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -29.1% | +74.4% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -29.1% over three years. Forward estimates point to Revenue at +74.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Opus Genetics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IRD's management, answered from reported figures.
Who manages IRD?
Opus Genetics, Inc. (IRD) lists 12 active executives. The top listed executive is Andrew Murphy, Chief Scientific Officer.
Are IRD insiders buying or selling?
Recent insider activity shows net selling of $15.21M.
Continue the stock analysis
Jump to another research area for this company.